Influenza
2023 Southern Hemisphere Seasonal Influenza Vaccine Antigens – Now available
To support the ongoing vaccine reformulation programmes, The Native Antigen Company is pleased to announce that Haemagglutinin (HA) and Neuraminidase (NA) antigens are now available to cover the 2023 southern hemisphere vaccine formulation.
Dengue Virus-Like Particles
Dengue Virus VLPs
Promotional offer for February and March 2023
Native Antigen Company offers an exclusive range of Virus Like Particles for all Dengue Virus serogroups.
Take advantage of our promotional offer.
33% off all Dengue VLP products for February and March.
New Virology Testing Services Available
The Native Antigen Company now offers a range of capabilities for virological research and the development of viral diagnostics, therapeutics, and vaccines.
About The Native Antigen Company
The Native Antigen Company develops and manufactures premium quality antigens and antibodies as well as offering a range of services to the diagnostic and biopharmaceutical industries.
Our proprietary VirtuE™ expression system has been developed for the purpose of producing native-like proteins, which are widely adopted by leading in vitro diagnostic, vaccine and academic groups in cutting-edge R&D, where correct folding and glycosylation are vital. Our contract services range from antibody generation, to scale production of recombinant and native antigens, and bespoke assay development and QC.
Building on our recognised expertise in infectious diseases, we are expanding our portfolio to include a range of disease-state markers and other critical reagents for human health.